A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors

What is the purpose of this trial?

To study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in patients with Advanced Solid Tumors

Participation Guidelines

Ages: 18 years and older

Gender: Both

Stemline Therapeutics, Inc.

Start Date: 08/19/2016

End Date: 06/30/2019

Last Updated: 04/23/2019

Study HIC#: 1511016798

Get Involved

For more information about this study, contact:
Nicole Sinclair
+1 203-737-1889

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Patricia LoRusso

Principal Investigator